A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Canc

Protocol No

LILLY-J3M-MC-JZQH

Staff Member

Hui-Zi Chen

Phase

III

Summary

This study aims to determine the efficacy of olomorasib in combination with standard of care immunotherapy following definitive NSCLC therapy.

Objective

Study of olomorasib combined with SOC immunotherapy for KRAS G12C-mutant NSCLC

Status

OPEN TO ACCRUAL

A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02